Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicopbacter pylori-negative subject: Effects of different regimens

Journal of Gastroenterology

Volumn 38, Issue 9, 2003, Pages 830-835

  Adachi, Kyoichi ^a   Komazawa, Yoshinori ^a   Fujishiro, Hirofumi ^a   Mihara, Takafumi ^a   Ono, Masahiro ^a   Yuki, Mika ^a   Kawamura, Akira ^a   Karim Rumi, Mohammad Azharul ^a   Amano, Yuji ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Helicobacter pylori; Nocturnal gastric acid breakthrough; pH monitoring; Rabeprazole; Ranitidine; Tolerance

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

AMBULATORY MONITORING; ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PEPTIC ULCER; PH MEASUREMENT; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PH; STOMACH SECRETION; VOLUNTEER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CHRONOTHERAPY; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; GASTRIC ACID; HELICOBACTER PYLORI; HUMANS; MALE; MONITORING, AMBULATORY; OMEPRAZOLE; RANITIDINE; REFERENCE VALUES;

EID: 10744225156     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1157-0     Document Type: Article

References (35)

1. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992;33:118-24.
2. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17:22-37.
3. Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996;91:1527-31.
4. Katzka DA, Paoletti V, Leite L, Castell DO. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol 1996;91:2110-3.
5. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-7.
6. Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987;28:1484-8.
7. Klinkenberg-Knol EC, Meuwissen SG. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990;4:485-95.
8. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastrooesophageal reflux disease. Digestion 1992;51(Suppl 1):59-67.
9. Hatlebakk JG, Berstad A. Endoscopic grading of reflux oesophagitis: what observations correlate with gastro-oesophageal reflux? Scand J Gastroenterol 1997;32:760-5.
10. Orr WC, Johnson L. Responses to different levels of esophageal acidification during waking and sleep. Dig Dis Sci 1998;43:241-5.
11. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994;89:989-91.
12. Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A, et al. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 2001;16:1191-6.
13. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-9.
14. Katsube T, Adachi K, Kawamura A, Amano K, Uchida Y, Watanabe M, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 2000;14:1049-56.
15. Nwokolo CU, Smith JT, Gavey C, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990;4(Suppl 1):29-45.
16. Hurlimann S, Abbuhl B, Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994;8:193-201.
17. Netzer P, Gaia C, Sandoz M, Huluk T, Gut A, Halter F, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999;94:351-7.
18. Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000;95:57-61.
19. Hall K, Perez G, Anderson D, Gutierrez C, Munson K, Hersey SJ, et al. Location of the carbohydrates present in the HK-ATPase vesicles isolated from hog gastric mucosa. Biochemistry 1990;29: 701-6.
20. Morii M, Takata H, Takeguchi N. Binding site of omeprazole in hog gastric H+,K(+)-ATPase. Biochem Biophys Res Commun 1990;167:754-60.
21. Sachs G, Wallmark B. The gastric H+,K+-ATPase: the site of action of omeprazole. Scand J Gastroenterol Suppl 1989;166:3-11.
22. Chiverton SG, Howden CW, Burget DW, Hunt RH. Omeprazole (20mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992;6:103-11.
23. Hongo M, Ohara S, Hirasawa Y, Abe S, Asaki S, Toyota T. Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing. Dig Dis Sci 1992;37:882-90.
24. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Double-blind comparison [correction of double-blind, placebo-controlled comparison] of rabeprazole 20mg vs omeprazole 20mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1999;13:49-57.
25. Katz PO, Anderson C, Khoury R, Castell DO. Gastrooesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998;12:1231-4.
26. Fouad YM, Katz PO, Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999;13:1467-71.
27. Werdmuller BF, Loffeld RJ. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997; 42:103-5.
28. Varanasi RV, Fantry GT, Wilson KT. Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease. Helicobacter 1998;3:188-94.
29. Koike T, Ohara S, Sekine H, Iijima K, Kato K, Shimosegawa T, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999;94:3468-72.
30. Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol 1999;34:553-9.
31. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-32.
32. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001;15: 1351-6.
33. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995;9:363-78.
34. Kuo B, Castell DO. Optimal dosing of omeprazole 40mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996;91:1532-8.
35. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40mg daily. Aliment Pharmacol Ther 1998;12:1235-40.